Laenssjukhuset I Kalmar Region Kalmar Laen

Kalmar 14 trials 8 recruiting

14 Registered trials

8 Currently recruiting

Organisation

Laenssjukhuset I Kalmar Region Kalmar Laen

Location

Kalmar, Sweden

Identifier

ORG-100042411

Address

Lasarettsvagen 8, Kalmar S:t Johannes, 392 44, Sweden

Departments

Barn- och ungdomskliniken Länssjukhuset 391 85 Kalmar
Department of Internal Medicine
Department of oncology
Dept. of Hematology
Infektionskliniken
Infektionsmottagning
Internal Medicine
Njurmedicin
Oncology
ÖNH-kliniken, Kalmar länssjukhus
Onkologiska kliniken, Länssjukhuset Kalmar
orthopedi
Pediatrics

Clinical trials at this site (14)

Search interface

Nordic PREdnisolon for VEstibular NeuriTis Study – an investigator-driven, triple blind, placebo controlled randomized trial Pending

2025-522399-10-00 Vestibular neuritis 5
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting

2023-508196-36-00 Follicular lymphoma 4 2025-05-27
Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated gl… Recruiting

2023-506998-35-00 Glioblastoma 5 2025-01-08
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 cutaneous malignant melanoma 5 2024-11-15
Can estimated glomerular filtration rate (eGFR) predict which patients with S. aureus-bacteremia that will need adjusted dosing via therapeu… Recruiting

2023-505148-20-00 Staphyloccus aureus bacteremia 6 2024-06-01
Alternative antibiotics to multidrug-resistant UTIs Recruiting

2024-513294-41-00 Urinary tract infection and/or bacteremia caused by ext 6 2023-04-17
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
Antibiotic Impregnated Bone Graft to reduce infection in hip replacement - the ABOGRAFT trial Recruiting

2024-510921-25-00 Prosthetic Joint Infection 4 2022-03-18
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Prostate Cancer 5 2019-01-08
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended

2023-509864-96-00 Mantle Cell Lymphoma (MCL) 4 2021-12-07
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
Evaluation of cortisone treatment in children suffering from acute facial nerve paralysis. Ended

2024-513430-37-00 Facial Nerve Palsy (Bells Palsy) 6 2019-06-01
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Ended

2024-515892-36-00 C3 glomerulopathy 4 2020-01-01
ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma … Ended

2022-501138-49-00 Follicular Lymphoma 4